Will Liraglutide Make It To WHO's Essential Medicines List?
Application Also Made For Inclusion Of CD19-directed CAR-Ts
Forthcoming review of WHO’s Model List of Essential Medicines is expected to consider glucagon-like peptide 1 receptor agonists such as Novo Nordisk’s liraglutide and also CAR-T therapies, among others. Scrip discusses with experts the prospects of their inclusion and the wider opportunities for industry.
